Close this search box.

파킨슨병 체외 모델

Parkinson’s disease (PD) is a slowly progressive neurodegenerative disease clinically characterized by progressive motor impairment in affected people. Synaptic and axonal degeneration is followed by loss of dopaminergic neurons in the substantia nigra leads to reduced levels of dopamine in the nigrostriatal circuitry. Besides dopaminergic cell loss, intracellular formation of Lewy bodies, consisting predominantly of aggregated alpha-synuclein, has been suggested to be crucial in the pathogenesis of this disease.

PD is a complex, multifactorial disease in which different factors concur to the pathogenic process. In vitro models (established cell lines, primary cell cultures or lesion models) offer the advantage of a controlled environment favorable for exploring single pathogenic mechanisms and the genes/proteins involved.

On the cellular level, research in PD focuses on:

  • Neurotoxicity (MPP+, 6-OHDA, BSO,…)
  • Excitotoxicity (NMDA, glutamate,…)
  • Mitochondrial dysfunction
  • Defects in protein degradation

Scantox offers several cellular solutions to model PD pathology in vitro:

The degeneration of midbrain dopaminergic neurons is the hallmark of the pathology of Parkinsons Disease (PD). Dopaminergic neurons represent less than 1% of the total number of neurons in the brain, though regulating such important brain functions as motor control, motivation, and working memory. Primary cultures constitute one of the most relevant models to investigate properties and characteristics of dopaminergic neurons.

QPS Austria provides primary dopaminergic TH (tyrosine hydroxylase) positive neurons from the ventral mesencephalon of rats. These cultures can be submitted to various stress agents that mimic PD pathology (MPP+, 6-OHDA) and to neuroprotective compounds in order to stop or slow down neuronal degeneration. A software supported automatic quantification method allows the determination of the following end points such as TH cell numbers, neurite outgrowth or apoptosis. A controlled regeneration or the prevention of degeneration of dopaminergic neurons are promising therapeutic approaches.

Number or positive TH Neurons

Figure: Effects of a developmental Compound X on the number of primary rat TH neurons from the ventral mesencephalon.

PD involves the degeneration of nigrostriatal dopaminergic (DA) neurons. This pathology can be modeled in experimental animals by the administration of MPTP (1-metyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine), a neurotoxin which is converted in the brain into MPP+ (1-methyl-4-phenylpyridinium) by the enzyme MAO-B a toxin which selectively destroys DA neurons and causes anatomical, behavioral, and biochemical changes similar to those seen in Parkinson’s disease.

In vitro Parkinsonism can be modeled by the administration of MPP+ to different cell culture systems. QPS Austria provides several cell culture models for MPP+ induced Parkinsonism, as primary cortical neurons (Figure), primary rat TH neurons, SH-SY5Y and many more.


Figure: Effects of known compounds as Trolox and MK-801 (left) and Compound X (right) on MPP+ induced toxicity in primary rat cortex neurons.

Primary fibroblasts available from patients clinically affected by:

  • Parkinson Disease (PD)
  • Leber’s Hereditary Optic Neuropathy (LHON)
  • Friedreich Ataxia (FRDA)

Skin fibroblasts present a system with defined mutations and the cumulative cellular damage of the patients and can thus serve as additional model to other cell systems as primary neurons or neuroblastoma cell lines.

To mimic disease related lesions of Parkinson‘s Disease, BSO (DL-buthionine-SR-sulfoximine) is applied for 48h to induce a toxic insult in PD cells. Cells are treated with or without Idebenone and cell viability is determined by MTT assay. Other possible toxic insults are available as MPP+, H2O2, Abeta1-42, 6-OHDA. Evaluation assays may range from cell viability to apoptosis assays or Mitochondrial related assays (activity, distribution, shape, membrane depolarization,…).

BSO Induced Toxicity

Figure: Effects of Idebenone on BSO induced neurotoxicity in human PD Fibroblasts.

요청사항이 있는 경우 John Yi 한국 에이전트(john.yi@atoxlab.co.kr)에게 한국어로 연락하십시오.

정보 요청

동물 모델

Scantox 는 형질전환 질병 모델을 생성하고, 특화하고, 유지하는 데 풍부한 경험이 있으며 20년이 넘도록 이를 신약 실험 프로젝트에 사용했습니다.
더 알아보기

조직학 서비스

Scantox 는 조직 표본 채취부터 실험 절차 및 결과가 모두 포함된 연구 보고서 제출에 이르는 전체 조직학 서비스를 제공합니다. 당사의 접근법은 고객의 특정 요구 사항에 따라 어떤 서비스든 맞춤화할 수 있는 일련의 절차적 구성 요소에 기반합니다. 고객은 당사의 워크플로우에서 시작점과 종점을 자유롭게 선택할 수 있습니다.
더 알아보기

바이오 마커

Scantox 는 다양한 질병 분석을 위한 분자 생물학적 방법에 있어 많은 선택지를 제공합니다. 해당 유닛은 QPS Neuropharmacology에서 수행하는 체외체내 연구를 지원합니다. 그리고 동일한 기술을 사용해 외부 전임상 연구 또는 임상 연구의 표본 분석을 정기적으로 수행합니다. 임상 표본뿐 아니라 전임상 체외 및 체내 연구에 동일한 분석 방법을 사용함으로써 고객 연구 프로젝트의 해석적 가치를 증가시킵니다.
더 알아보기